NASDAQ:SGMT Sagimet Biosciences (SGMT) Stock Price, News & Analysis → The ONE AI Stock to own now. (It’s not Nvidia.) (From Weiss Ratings) (Ad) Free SGMT Stock Alerts $4.44 -0.13 (-2.84%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$4.36▼$4.7350-Day Range$3.90▼$6.6752-Week Range$2.13▼$20.71Volume374,056 shsAverage Volume434,938 shsMarket Capitalization$141.68 millionP/E RatioN/ADividend YieldN/APrice Target$39.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Sagimet Biosciences alerts: Email Address Sagimet Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside791.9% Upside$39.60 Price TargetShort InterestBearish12.78% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.79Based on 10 Articles This WeekInsider TradingAcquiring Shares$63,767 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.17) to ($3.96) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.55 out of 5 starsMedical Sector487th out of 925 stocksPharmaceutical Preparations Industry222nd out of 430 stocks 3.5 Analyst's Opinion Consensus RatingSagimet Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSagimet Biosciences has only been the subject of 4 research reports in the past 90 days.Read more about Sagimet Biosciences' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted12.78% of the float of Sagimet Biosciences has been sold short.Short Interest Ratio / Days to CoverSagimet Biosciences has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sagimet Biosciences has recently increased by 6.28%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSagimet Biosciences does not currently pay a dividend.Dividend GrowthSagimet Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SGMT. Previous Next 2.7 News and Social Media Coverage News SentimentSagimet Biosciences has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Sagimet Biosciences this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for SGMT on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Sagimet Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -38% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sagimet Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $63,767.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders17.60% of the stock of Sagimet Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions87.86% of the stock of Sagimet Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sagimet Biosciences' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Sagimet Biosciences are expected to decrease in the coming year, from ($2.17) to ($3.96) per share.Price to Book Value per Share RatioSagimet Biosciences has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Sagimet Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About Sagimet Biosciences Stock (NASDAQ:SGMT)Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.Read More SGMT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SGMT Stock News HeadlinesMay 7, 2024 | finance.yahoo.comSagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024May 6, 2024 | marketwatch.comSagimet Biosciences Names Thierry Chauche Chief Financial OfficerMay 12, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).May 6, 2024 | finanznachrichten.deSagimet Biosciences Inc.: Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial OfficerMay 6, 2024 | globenewswire.comSagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial OfficerMay 6, 2024 | americanbankingnews.comSagimet Biosciences (NASDAQ:SGMT) Now Covered by HC WainwrightMay 6, 2024 | americanbankingnews.comSagimet Biosciences Inc. Expected to Post Q1 2024 Earnings of ($0.41) Per Share (NASDAQ:SGMT)May 2, 2024 | msn.comHC Wainwright & Co. Initiates Coverage of Sagimet Biosciences (SGMT) with Buy RecommendationMay 12, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).April 22, 2024 | globenewswire.comSagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024March 28, 2024 | finance.yahoo.comSagimet Biosciences Inc (SGMT) Reports Full Year 2023 Financial Results: A Close LookMarch 27, 2024 | globenewswire.comSagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor DenifanstatMarch 25, 2024 | markets.businessinsider.comStrong Buy Recommendation: Sagimet Biosciences’ Unique NASH Drug and Solid Financials Signal Market Growth PotentialMarch 25, 2024 | markets.businessinsider.comSagimet Biosciences: Strong Buy on Robust Financials and Promising NASH Drug TrialsMarch 25, 2024 | msn.comSagimet Biosciences GAAP EPS of -$2.66 beats by $34.65, revenue of $2M in-lineMarch 25, 2024 | globenewswire.comSagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of DirectorsMarch 25, 2024 | globenewswire.comSagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate UpdatesFebruary 29, 2024 | globenewswire.comSagimet Biosciences to Participate in Two Upcoming Investor ConferencesFebruary 25, 2024 | benzinga.comSagimet Biosciences Stock (NASDAQ:SGMT) Dividends: History, Yield and DatesFebruary 24, 2024 | msn.comSagimet Biosciences (SGMT) Price Target Increased by 17.19% to 51.00February 23, 2024 | finance.yahoo.comPainful week for retail investors invested in Sagimet Biosciences Inc. (NASDAQ:SGMT) after 22% drop, institutions also suffered lossesFebruary 17, 2024 | morningstar.comSagimet Biosciences Inc Class A Shares SGMTFebruary 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Sagimet Biosciences as Phase 2b Results of Denifanstat Outshine CompetitorsFebruary 6, 2024 | realmoney.thestreet.comSagimet Biosciences price target lowered by $1 at JMP Securities, here's whyFebruary 6, 2024 | finance.yahoo.comSteven Cohen's Point72 Asset Management Acquires New Stake in Sagimet Biosciences IncFebruary 3, 2024 | msn.comSagimet Biosciences Announces Interim CFO AppointmentJanuary 30, 2024 | uk.finance.yahoo.comSagimet Biosciences Inc. (SGMT)See More Headlines Receive SGMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sagimet Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/21/2023Today5/12/2024Next Earnings (Estimated)6/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SGMT CUSIPN/A CIK1400118 Websagimet.com Phone650-561-8600FaxN/AEmployees8Year FoundedN/APrice Target and Rating Average Stock Price Target$39.60 High Stock Price Target$67.00 Low Stock Price Target$26.00 Potential Upside/Downside+791.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio17.09 Quick Ratio17.09 Sales & Book Value Annual Sales$2 million Price / Sales70.84 Cash FlowN/A Price / Cash FlowN/A Book Value$3.98 per share Price / Book1.12Miscellaneous Outstanding Shares31,910,000Free Float26,297,000Market Cap$141.68 million OptionableNot Optionable BetaN/A Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. George W. Kemble Ph.D. (Age 62)Executive Chairman of the Board Comp: $484kMr. David A. Happel (Age 62)CEO, President & Director Comp: $836.18kDr. Eduardo Bruno Martins DPhil (Age 61)M.D., Ph.D., Chief Medical Officer Comp: $649.33kMr. Urs Greber Ph.D.Co-FounderDr. Lucas Pelkmans Ph.D.Co-FounderMr. Joseph Oriti (Age 44)Interim Principal Financial Officer & Interim Principal Accounting Officer Ms. Elizabeth Rozek Esq. (Age 52)J.D., General Counsel & Chief Compliance Officer Dr. Marie O'Farrell Ph.D.Senior Vice President of Research & DevelopmentMore ExecutivesKey CompetitorsI-MabNASDAQ:IMABRegulus TherapeuticsNASDAQ:RGLSCervoMedNASDAQ:CRVOSkye BioscienceNASDAQ:SKYEInterCureNASDAQ:INCRView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 894,319 shares on 5/10/2024Ownership: 3.570%Acadian Asset Management LLCBought 34,929 shares on 5/10/2024Ownership: 0.109%David HappelBought 12,100 shares on 3/26/2024Total: $63,767.00 ($5.27/share)Platinum Investment Management Ltd.Sold 272,161 shares on 2/14/2024Ownership: 0.523%David HappelBought 590 shares on 11/16/2023Total: $1,386.50 ($2.35/share)View All Insider TransactionsView All Institutional Transactions SGMT Stock Analysis - Frequently Asked Questions Should I buy or sell Sagimet Biosciences stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sagimet Biosciences in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SGMT shares. View SGMT analyst ratings or view top-rated stocks. What is Sagimet Biosciences' stock price target for 2024? 7 analysts have issued 12-month price targets for Sagimet Biosciences' shares. Their SGMT share price targets range from $26.00 to $67.00. On average, they predict the company's share price to reach $39.60 in the next twelve months. This suggests a possible upside of 791.9% from the stock's current price. View analysts price targets for SGMT or view top-rated stocks among Wall Street analysts. How have SGMT shares performed in 2024? Sagimet Biosciences' stock was trading at $5.42 at the beginning of the year. Since then, SGMT stock has decreased by 18.1% and is now trading at $4.44. View the best growth stocks for 2024 here. When is Sagimet Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, June 24th 2024. View our SGMT earnings forecast. How were Sagimet Biosciences' earnings last quarter? Sagimet Biosciences Inc. (NASDAQ:SGMT) posted its quarterly earnings results on Monday, August, 21st. The company reported ($35.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by $35.30. When did Sagimet Biosciences IPO? Sagimet Biosciences (SGMT) raised $85 million in an initial public offering on Friday, July 14th 2023. The company issued 5,312,500 shares at $16.00 per share. Who are Sagimet Biosciences' major shareholders? Sagimet Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.57%) and Acadian Asset Management LLC (0.11%). Insiders that own company stock include Beth C Seidenberg, David Happel and Enterprise Associates 13 L New. View institutional ownership trends. How do I buy shares of Sagimet Biosciences? Shares of SGMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SGMT) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsCollapse of the Petrodollar Colonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsGold Set to EXPLODE!Gold Safe Exchange[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICMissed NVDA? Buy this AI stock NOWChaikin AnalyticsYou need to know these two things about AI stocks ASAP…InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sagimet Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
